Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $36.1, Implies 176% Upside

What happened

The average 12-month price target for Syndax Pharmaceuticals from 10 analysts fell to $36.1 from $37.9, with forecasts ranging from $17 to $57 per share. Based on the Nov. 2 closing price, the target implies about 176% upside.

Confirmed

Global impact / market context

A lower average target means analysts collectively expect less upside than before, though the $36.1 figure still implies large potential gains. The all-Buy rating suggests continued positive views, so the cut may reflect smaller adjustments to expectations rather than a change in overall opinion.

Analyst inference

The wide $17 to $57 forecast range shows analysts disagree substantially about Syndax's future value. The unchanged Buy consensus across 11 analysts, alongside the reduced target, suggests views remain positive but somewhat less optimistic than earlier estimates implied.

Analyst inference

What to watch

1. Watch whether the average price target changes again as analysts update estimates, since the current figure of $36.1 already reflects a reduction from $37.9. Confirmed
2. Track whether any of the 11 covering analysts change their Buy ratings, because a shift away from the unanimous Buy consensus would signal a change in views. Proposed
3. Monitor whether the gap between the lowest $17 and highest $57 forecasts narrows, which would suggest analysts are converging on a clearer view of the company's prospects. Analyst inference

Evidence

• Original source link unavailable